Apatinib for Resectable Colorectal Cancer
Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.

Language: English.
Apatinib|Outcome, Fatal|Colorectal Cancer|Surgery|Adjuvant Chemotherapy
DRUG: Apatinib|DRUG: CAPEOX
Number of Participants recurrence-free survival, Number of Participants recurrence-free survival in intervention group and control group., 1 year|Number of Participants overall survival, Number of Participants overall survival in intervention group and control group., 1 year
Number of Participants recurrence-free survival, Number of Participants recurrence-free survival in intervention group and control group., 2 years|Number of Participants overall survival, Number of Participants overall survival in intervention group and control group., 2 years
Number of Participants recurrence-free survival, Number of Participants recurrence-free survival in intervention group and control group., 3 years|Number of Participants overall survival, Number of Participants overall survival in intervention group and control group., 3 years|Number of Participants recurrence-free survival, Number of Participants recurrence-free survival in intervention group and control group., 4 years|Number of Participants overall survival, Number of Participants overall survival in intervention group and control group., 4 years|Number of Participants recurrence-free survival, Number of Participants recurrence-free survival in intervention group and control group., 5 years|Number of Participants overall survival, Number of Participants overall survival in intervention group and control group., 5 years
Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.

Language: English.